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1. Introduction 
An endogeneous pentapeptide with opiate agonist 
activity, identified as residues 6 l-65 of porcine 
pituitary P-lipotropin, has been isolated and charac- 
terized by Hughes et al. [ 11. Since then, several frag- 
ments of the C-terminal portion of P-LPH molecule 
have been shown to possess morphine-like activity 
in different assay systems [2-lo]. 
The two in vitro preparations used most frequently 
for the demonstration of opioid activity of alkaloids, 
semisynthetic and synthetic narcotic derivatives as 
well as that of natural and synthetic peptides, are the 
longitudinal muscle of guinea-pig ileum and the mouse 
vas deferens [1,4,8,1 l-171. The relative potencies of 
non-peptide narcotics in guinea-pig ileum and mouse 
vas deferens are rather similar [13,14] with the 
exception of some cyclazocine-derivatives [171. 
Furthermore, there is also a fair agreement so far as 
the relative potencies of shorter synthetic peptides 
similar to LPH-(61-65)peptide, are concerned [16]. 
The aim of this study was to determine the 
relative potencies of larger active fragments of P-LPH 
in these two biological models. The potency ratios 
were found to be similar in both preparations for 
LPH-(61-69) and LPH-(61-79)peptides as compared 
to LPH-(61-65)peptide, whilst in the case of 
LPH-(61-91)peptide there was an apparent diver- 
gence between the two systems. 
2. Experimental 
LPH-(61-65)Peptide was synthesized as described 
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previously [4]. LPH-(61-79)Peptide was obtained by 
plasmin cleavage of fl-LPH [18,19]. LPH-(61-91) 
Peptide was prepared from porcine pituitary gland 
[20]. The longitudinal muscle strip of guinea-pig ileum 
was prepared as described by Paton and Vizi [21]. The 
morphine-like activity was measured according to 
Kosterlitz and Watt [ 111. For the comparison of the 
agonist potencies of the peptides, the single-dose 
method [I l] was not used, but complete dose- 
response curves were constructed. The mouse vas 
deferens was prepared according to Hughes et al. [ 121 
and bathed at 3 1°C in modified Krebs’ solution [ 121. 
We have slightly modified the parameters of the 
stimulation applied. Field electrical stimulation was 
used, delivered through platinum wire electrodes 
positioned at the top and the bottom of the organ bath. 
The upper electrode was a ring of 4 mm diameter. 
Paired shocks with 100 ms delay between the rectan- 
gular pulses of 1 ms were used, delivered at a rate of 
0.1 Hz. 
3. Results 
Table 1 contains the relative agonist potencies of 
four active @LPH fragments in guinea-pig ileum and 
mouse vas deferens. It can be seen, that the relative 
potencies of LPH-(61-69)- and LPH-(61-79)peptides 
are similar in the two in vitro models. The increment 
in the chain length led to the decrease of the agonist 
potency in both assay systems. 
Introduction of residues 80.-9 1 to the molecule, 
however, resulted in an apparent divergence between 
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Table 1 
The relative agonist potencies of four p-LPH fragments in longitudinal muscle strip of 
guinea-pig ileum and mouse vas deferens 
Peptidc Relative agonist potency (Met-enkephalin = 100) GPI/MDV 
Guinea-pig ileum Mouse vas deferens 
(GPI) (MDV) 
- 
LPH-(61-65) 1ooa IOOb 
(Met-enkephalin) (n =4) (n = 14) 
LPH-(6 l-69) 44c 35d 1.3 
(n =4) (n =4) 
LPH-(6 I-79) 39 3.5 1.1 
(n = 7) (n =4) 
LPH-(61-91) 130 5 26.0 
(n =4) (n = 8) 
a The ID,, of LPH-(61-65)-peptide was as high as 113.2 ? 22.5 nM (n = 4) 
b The ID,, of LPH-(61-65)-peptide was 4.2 f 0.4 nM (n = 14) 
’ LPH-(61-69)-peptide was a purified material [6 ] 
d A tryptic digest of fl-LPH was used [22] without further purification 
Purified LPH-(61-69)-peptide and the complete tryptic digest of @LPN exerted qualita- 
tively and quantitatively identical effects in the biological systems investigated 
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the two preparations. While in the longitudinal muscle 
strip of guinea-pig ileum the agonist activity of 
LPH-(61-9l)peptide was higher than that of 
LPH-(61-79)peptide, there was a further loss in the 
potency in mouse vas deferens. Tryptic cleavage of 
LPH-(61-91)peptide led to the appearance of the 
agonist potency corresponding to LPH-(6 l-69) 
peptide in both preparations. None of the compounds 
studied possessed measurable antagonist activity in 
any of the systems used. 
4. Discussion 
According to our previous study on the analgesic 
activities of these peptides [8], increase of the chain 
length from residues 61-65 to residues 6 l-69 and 
61-79 enhanced analgesic potency and the introduc- 
tion of residues 80-9 1, led to a further dramatic 
increase in the analgesic activity. 
Previous speculations on the conformation of 
peptides possessing opiate activity are in agreement 
concerning the significance of the tyramine moiety 
of the compounds at sequence position 61 [23-261. 
Further receptor binding sites of hydrophobic 
character are provided by the Pheeg and Metes side- 
chains. Furthermore, a well-defined secondary 
structure was proposed for LPH-(61-65)peptide, 
characterized by a P-turn, which is stabilized by a 
hydrogen-bond between the carbonyl-group of Gly,, 
and the imino-group Meta [25,26] or between the 
CO of Tyr6r and the NH of Pheti [23]. 
Practically no information has been available so 
far as the steric structure of larger lipotropin fragments 
is concerned. It might be speculated that the relatively 
weaker potency of LPH-(61-69> and LPH-(61-79) 
peptides, as compared to that of LPH-(61-65)pep- 
tide in isolated systems, may be due to a steric 
hindrance of the opiate receptor-active site interac- 
tion caused by the additional residues of the parent 
peptides [8]. Some of our unpublished data show, in 
agreement with the proposal of Hambrook et al. [27], 
that the common NH*-terminal Tyr residue of all the 
peptides studied, is highly accessible to the action of 
aminopeptidase M. That is, this residue could easily 
be removed from the peptide chains by the enzyme. 
In addition, aminopeptidase M completely hydrolyzed 
LPH-(61-65) and LPH-(61-79)peptides. The 
segment between residues 62-79 in LPH-(61-91) 
peptide, however, proved to be partially protected 
against the action of aminopeptidase M, which may 
be regarded as an indication of an intramolecular 
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interaction between this portion and the C-terminal 
part of the molecule. This change in the steric 
structure may be in favour of binding to the receptors 
in longitudinal muscle strip and, at the same time, 
disadvantageous for the interaction of the molecule 
with the receptors in mouse vas deferens. In the 
in vivo efficacy of the peptides, factors other than 
the affinity to the receptors (i.e., protection of 
the molecules from rapid inactivation [5,8,27] and 
the access of the peptides to the receptor sites) have 
to be taken into consideration. 
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